Core Insights - Teladoc Health, Inc. is set to release its fourth-quarter 2025 earnings on February 25, 2026, with analysts predicting an earnings per share (EPS) of -$0.19, reflecting a 32.1% improvement from the previous year [1][6] Financial Performance - Revenue for the fourth quarter is projected to be $633.91 million, indicating a slight 1% decline from the same period last year [2][6] - For the full year 2025, revenues are estimated at $2.52 billion, which represents a 1.9% decline from the previous year [4] Segment Analysis - The Integrated Care segment is expected to grow, with membership projected to increase by 9.1% and segment EBITDA anticipated to rise by 20.9% year-over-year [3][6] - Conversely, the BetterHelp segment is facing challenges, with expected revenue declines of 6.2% and a 5% decrease in paying users for the fourth quarter [3] Financial Metrics - The company has a negative price-to-earnings (P/E) ratio of -3.57, indicating a lack of profitability [5] - The price-to-sales ratio stands at 0.32, suggesting that investors are paying $0.32 for every dollar of sales [5] - A debt-to-equity ratio of 0.75 indicates a moderate level of debt, while a current ratio of 2.70 reflects a strong ability to cover short-term liabilities [5]

Teladoc Health, Inc. (NYSE:TDOC) is one of the 13 Best American Penny Stocks to Invest In. On January 27, BofA Securities reduced its price target on Teladoc Health, Inc. (NYSE:TDOC) from $7.50 to $7 and kept its Neutral rating on the stock. BofA Securities pointed out that BetterHelp’s monthly active users in Q4 are tracking 0.2% above Q3 levels but 18.7% down compared to the same period last year. Despite year-over-year trends being a little worse than in the previous quarter, BofA sees the flat growth ...

Core Viewpoint - Teladoc Health has experienced a significant decline in market value, losing over 98% in the past five years, and is struggling to regain its previous success during the pandemic [1] Industry Overview - Demand for telemedicine services peaked during the pandemic, with usage increasing from 5% pre-pandemic to 42.1% during, and settling at 21.8% post-pandemic, which is still above pre-2019 levels [3] - The telemedicine sector is facing intense competition, particularly from larger corporations like Amazon, which poses challenges for Teladoc's growth, especially in its virtual therapy service, BetterHelp [4] Company Initiatives - Teladoc is attempting to address competition by seeking third-party coverage for BetterHelp to enhance demand and has launched new services such as continuous health monitoring and chronic care [5] - The company is also expanding internationally, with international revenue growing faster than domestic revenue in recent quarters [5] Financial Performance - Despite efforts to grow, Teladoc's revenue is increasing slowly, and the company is currently operating at a loss, with concerns that international expansion may lead to similar challenges as faced domestically [7] - The company has not yet secured broad health insurance coverage for its therapy services, even after acquiring UpLift, which has 100 million covered lives, indicating that third-party coverage does not guarantee demand or revenue [8] Future Outlook - The outlook for Teladoc appears bleak, with significant challenges ahead, and the stock price recently trading at $4.90, raising concerns that it could approach $0 in the next five years [9]

Core Insights - Teladoc Health, Inc. (TDOC) is expected to report a fourth-quarter 2025 loss of 19 cents per share on revenues of $633.91 million, with a year-over-year revenue decrease of 1% [1][2][7] Financial Performance - The fourth-quarter earnings estimate has improved by a penny over the past 60 days, indicating a year-over-year improvement of 32.1% in the bottom line [2] - For the full year 2025, the Zacks Consensus Estimate for Teladoc's revenues is $2.52 billion, reflecting a decline of 1.9% year over year, while the EPS estimate is a loss of $1.20, showing an improvement of 79.6% year over year [3] Earnings Expectations - Teladoc has beaten earnings estimates in three of the last four quarters, with an average surprise of 14.5% [3] - The company has an Earnings ESP of 0.00% and a Zacks Rank of 2 (Buy), which does not conclusively predict an earnings beat this time [4] Segment Performance - Integrated Care members are expected to increase by 9.1%, with segment EBITDA rising by 20.9% year over year [7][10] - BetterHelp revenue is projected to decline by 6.2%, with paying users down by 5% in Q4, and the adjusted EBITDA from this segment is expected to fall by 28.9% year over year [9][10] Revenue Breakdown - The Zacks Consensus Estimate for fourth-quarter Access fees revenues indicates a 1.3% year-over-year decline, while U.S. operations are expected to have declined, partially offset by increased revenues from international operations [8] - Overall adjusted EBITDA is expected to be between $73 million and $90 million, with free cash flow for the full year 2025 projected to be between $170 million and $185 million [10]

Group 1 - Teladoc Health Inc. is considered one of the best single-digit stocks to buy according to analysts, with recent price target adjustments reflecting market conditions [1] - Bank of America analyst Allen Lutz lowered the price target for Teladoc to $7 from $7.50, maintaining a Neutral rating, citing trends indicating Q4 2025 revenue may align with consensus but fall slightly below Teladoc's guidance [1] - Goldman Sachs also lowered its price target for Teladoc from $9 to $8 while keeping a Buy rating, noting a sharp decline in MedTech and Healthcare IT stocks that is believed to be disconnected from company fundamentals [2] Group 2 - Citi analyst Daniel Grosslight reduced the price target for Teladoc from $10 to $9, maintaining a Neutral rating, and expressed cautious optimism for a potential recovery in 2026 despite a challenging 2025 for the health tech sector [3] - The health tech and distribution sector faced significant challenges in 2025, with nearly a third of the group experiencing declines of more than 25% [3] - Teladoc operates globally, providing virtual healthcare services through its Integrated Care and BetterHelp segments [4]

Core Insights - Teladoc Health has appointed Michael Smith to its board of directors, bringing over three decades of leadership experience in financial management and strategic transformation [1][2] - Smith's expertise in enterprise transformations is expected to enhance Teladoc's strategic focus for long-term growth as the company continues to scale and innovate [2] - Teladoc Health will release its fourth quarter 2025 results on February 25, 2026, followed by a conference call to discuss the results [3] Company Overview - Teladoc Health is recognized as the global leader in virtual care, facilitating care delivery across various stakeholders including patients, care providers, and health systems [4] - The company aims to improve access to care, drive better health outcomes, extend provider capacity, and reduce costs through its innovative virtual care solutions [4]

Core Viewpoint - Teladoc Health, once thriving during the COVID-19 pandemic, is now facing stagnant and declining revenue, leading to concerns about its long-term viability as a company [1][12]. Company Overview - Founded in 2002, Teladoc Health specializes in remote medical appointments and had a successful IPO in 2015, experiencing steady share price growth until the pandemic [2]. - The company's stock price surged 224% from approximately $81 per share in late 2019 to a peak of $263 per share in January 2021 [4]. Current Financial Performance - By the end of 2023, Teladoc's share price had plummeted to $21, representing a 92% decrease from its peak [5]. - As of the latest data, the stock trades around $5, with a market capitalization of $861 million [6][7]. - Revenue for 2023 was reported at $2.6 billion, which is projected to decline by 1% to $2.5 billion in 2024, with further decreases anticipated in subsequent quarters [10]. Competitive Landscape - Teladoc faces significant competition from other telemedicine providers and traditional in-person medical services, with 71% of patients preferring in-person visits according to the National Institutes of Health [8][9]. - The company has struggled to maintain its market position as telemedicine becomes less dominant post-pandemic [9]. Profitability Challenges - Teladoc has never achieved profitability, with a net profit margin of negative 21% during its peak in 2021, improving slightly to negative 8.8% but still indicating ongoing financial struggles [11]. - The company is characterized by a lack of growth and profitability, raising concerns about its future sustainability [12].

Core Viewpoint - Teladoc Health Inc. is set to release its fourth quarter 2025 results on February 25, 2026, after market close, followed by a conference call to discuss the results [1]. Group 1: Conference Call Details - The conference call will be accessible by dialing 1-833-470-1428 for U.S. participants, with an access code of 330912 [2]. - International participants can find global dial-in numbers through a provided link [2]. - A live audio webcast will be available online for the conference call [2]. Group 2: Replay Information - A replay of the conference call will be available via webcast shortly after the call concludes and will remain accessible for approximately 90 days [3]. Group 3: Company Overview - Teladoc Health is recognized as the global leader in virtual care, focusing on transforming virtual care into a catalyst for improved health outcomes [4]. - The company collaborates with health plans, employers, providers, health systems, and consumers to enhance access, drive better outcomes, extend provider capacity, and reduce costs [4].

Group 1 - Teladoc Health, Inc. (NYSE:TDOC) has faced significant stock losses, with one investor reporting a nearly 96% loss in their IRA investment [1] - Jim Cramer advised against holding Teladoc stock, suggesting there are better alternatives in the market [1] - Teladoc provides virtual medical care services, including chronic condition management, mental health support, and specialized therapy [3] Group 2 - There is a belief that certain AI stocks present greater upside potential and carry less downside risk compared to Teladoc [4] - The article hints at the potential of AI stocks benefiting from trends such as Trump-era tariffs and onshoring [4]

Core Viewpoint - Teladoc's stock price has significantly declined, reaching a record low due to decreased demand for its services post-pandemic, falling to $5.74 from an all-time high of $308 [1] Company Summary - Teladoc's market capitalization has been adversely affected by the drop in stock price, indicating a substantial loss in investor confidence and market value [1]